×

Do you want to link to this External Website and leave Amgen.nl?

YOU ARE NOW LEAVING THIS WEBSITE. Amgen Netherlands takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Wilt u deze Externe Website bezoeken en Amgen.nl verlaten?

U verlaat nu de website van Amgen Nederland. Amgen Nederland draagt geen verantwoordelijkheid voor, en oefent geen controle uit, over de organisaties, meningen or juistheid van de informatie van deze server of website.

Kidney disease



Aranesp is a medicine to treat anemia. Anemia is when your blood does not contain enough red blood cells and the symptoms may be fatigue, weakness and shortness of breath.Aranesp is used to treat symptomatic anemia that is associated with chronic renal failure (kidney failure) in adults and children. Aranesp is also used to treat symptomatic anemia in adult cancer patients with non-myeloid malignancies who are receiving chemotherapy.

Aranesp is a medicine which contains the active substance darbepoetin alfa, a product to treat anemia.Anemia is when your blood does not contain enough red blood cells and the symptoms may be fatigue, weakness and shortness of breath.

Aranesp works in exactly the same way as the natural hormone erythropoietin.Erythropoietin is produced in your kidneys and encourages your bone marrow to produce more red blood cells. The active substance of Aranesp is darbepoetin alfa produced by gene-technology in Chinese Hamster Ovary Cells (CHO-K1).

If you have chronic renal failure

Aranesp is used to treat symptomatic anemia that is associated with chronic renal failure (kidney failure) in adults and children. In kidney failure, the kidney does not produce enough of the natural hormone erythropoietin which can often cause anemia.

Because it will take your body some time to make more red blood cells, it will be about four weeks before you notice any effect.Your normal dialysis routine will not affect the ability of Aranesp to treat your anemia.

If you are receiving chemotherapy

Aranesp is used to treat symptomatic anemia in adult cancer patients with non-bone marrow cancers (non-myeloid malignancies) who are receiving chemotherapy. One of the main side effects of chemotherapy is that it stops the bone marrow producing enough blood cells.

Towards the end of your chemotherapy course, particularly if you have had a lot of chemotherapy, your red blood cell count may fall making you anemic.

    Mimpara is used (in adults):
  • to treat secondary hyperparathyroidism in adults with serious kidney disease who need dialysis to clear their blood of waste products.
  • to reduce high levels of calcium in the blood (hypercalcemia) in adult patients with parathyroid cancer.
  • to reduce high levels of calcium in the blood (hypercalcemia) in adult patients with primary hyperparathyroidism when removal of the gland is not possible.

Mimpara is used in children aged 3 years to less than 18 years of age: to treat secondary hyperparathyroidism in patients with serious kidney disease who need dialysis to clear their blood of waste products, whose condition is not controlled with other treatments.

Mimpara works by controlling the levels of parathyroid hormone (PTH), calcium and phosphorous in your body.It is used to treat problems with organs called parathyroid glands. The parathyroids are four small glands in the neck, near the thyroid gland, that produce parathyroid hormone (PTH).

Mimpara is used (in adults):

  • to treat secondary hyperparathyroidism in adults with serious kidney disease who need dialysis to clear their blood of waste products.
  • to reduce high levels of calcium in the blood (hypercalcemia) in adult patients with parathyroid cancer.
  • to reduce high levels of calcium in the blood (hypercalcemia) in adult patients with primary hyperparathyroidism when removal of the gland is not possible.
  • Mimpara is used in children aged 3 years to less than 18 years of age: to treat secondary hyperparathyroidism in patients with serious kidney disease who need dialysis to clear their blood of waste products, whose condition is not controlled with other treatments.

In primary and secondary hyperparathyroidism too much PTH is produced by the parathyroid glands.

“Primary” means that the hyperparathyroidism is not caused by any other condition and “secondary” means that the hyperparathyroidism is caused by another condition, e.g. kidney disease.

Both primary and secondary hyperparathyroidism can cause the loss of calcium in the bones, which can lead to bone pain and fractures, problems with blood and heart vessels, kidney stones, mental illness and coma.

Parsabiv is used to treat secondary hyperparathyroidism in patients with serious kidney disease who need hemodialysis to clear their blood of waste products.

Parsabiv contains the active substance etelcalcetide, which reduces parathyroid hormone known as PTH. Parsabiv is used to treat secondary hyperparathyroidism in patients with serious kidney disease who need hemodialysis to clear their blood of waste products.In secondary hyperparathyroidism too much PTH is produced by the parathyroid glands (four small glands in the neck).

“Secondary” means that the hyperparathyroidism is caused by another condition, e.g. kidney disease. Secondary hyperparathyroidism can cause the loss of calcium from the bones, which can lead to bone pain and fractures and problems with blood and heart vessels. By controlling the levels of PTH, Parsabiv helps to control calcium and phosphate in your body.


Source: Patient information leaflets, Amgen. See www.ema.europa.eu for the most up-to-date versions.